Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics to Collaborate with Columbia U. on Lymphoma Biomarkers

NEW YORK (GenomeWeb News) - Rosetta Genomics will collaborate with Columbia University to develop microRNA-based diagnostic tests for early detection and prognosis of certain types of non-Hodgkin lymphoma and leukemia, Rosetta said today.
 
Under the collaboration, Rosetta Genomics and Columbia researchers will screen for microRNAs that could serve as biomarkers and drug targets for diffuse large cell lymphoma, transformed follicular lymphoma, and chronic lymphocytic leukemia.
 
According to Rosetta Genomics Head of Global R&D Dalia Cohen, 40 percent of DLCL patients respond well to current therapies and have prolonged survival, but researchers do not know why the remainder of patients don’t respond to therapy. "We believe our technology will help answer this question, as well as speed up and simplify the diagnostic process,” Cohen said.
 
The American Cancer Society estimates that around 43,000 people in the US will be diagnosed with these cancers in 2007.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.